Artículos discutidos

| ensayo | revisión | diagnóstico | pronóstico | económica | series de casos | otros |

Artículos de tipo 'económica' discutidos:

  • 5.- Mason JM, Wakeman AP, Drumond MF, Crump BJ. Population screening for abdominal aortic aneurysm: do the benefits outweigh the cost? Journal of Public Health Medicine 1993; 15: 154-160
  • 6.- Ortega A, Dramitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophilactic epoetin alfa? A cost-benefit analysis. Cancer 1998;83:2588-2596.
  • 63.- Manns BJ, Lee H, Doig ChJ, et al. An Economic Evaluation of Activated Protein C Treatment for Severe Sepsis. N Engl J Med, 2002;347(13);993-1000.
  • 69.- Prosser L.A, Stinnett A.A, Goldman P.A, Williams L.W, Hunink M.G.M, Goldman L, Weinstein M.C. Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics. Ann Intern Med 2000; 132: 769-779.
  • 70.- Kuntz, KM, Fleischmann KE, Hunink MGM, Douglas PS. Cost - Effectiveness of Diagnostic Strategies for Patients with Chest Pain. Ann Intern Med 1999; 130: 709-718.
  • 90.- Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. CDC Diabetes Cost-effectiveness Group JAMA 2002; 187: 2543-51.
  • 123.- O´Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706
  • 166.- Cost effectiveness of nurse led secondary prevention clinics for
    coronary heart disease in primary care: follow up of a randomised
    controlled trial
    James P Raftery, Guiqing L Yao, Peter Murchie, Neil C Campbell, Lewis D Ritchie. BMJ 2005; 330: 707-10
  • 225.- Gene E., Calvet X., Azagra R., Gisbert J.P. ¿Siete o diez días? Estudio de coste-efectividad sobre la duración del tratamiento de la infección por H. pylori en atención primaria. Aten Primaria. 2006 Dec;38(10):555-62
  • 231.- Michael Pignone; Stephanie Earnshaw; Mark J. Pletcher; Jeffrey A. Tice. Aspirin for the Primary Prevention of Cardiovascular Disease in Women: A Cost-Utility Analysis. Arch Intern Med. 2007;167(3):290-295.
←1 2 →